Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017
Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported net revenue was $38,908,000 compared with $13,574,000 a year ago. Loss from operations was $13,964,000 against $14,360,000 a year ago. Loss before provision for income taxes was $24,747,000 compared with $19,351,000 a year ago. Net loss was $24,568,000 against $19,920,000 a year ago. Basic and diluted net loss per share was $1.32 compared with $1.48 a year ago. Non-GAAP net loss was $3,317,000 against $20,094,000 a year ago. Non-GAAP basic net loss per share was $0.18 against $1.50 a year ago. On a pro forma basis, net loss in the fourth quarter of 2017 was $3.3 million, compared to $20.1 million for the same period in 2016.
For the full year, the company reported net revenue was $138,438,000 compared with $13,574,000 a year ago. Loss from operations was $86,798,000 against $36,706,000 a year ago. Loss before provision for income taxes was $126,127,000 compared with $52,405,000 a year ago. Net loss was $126,710,000 against $52,870,000 a year ago. Basic and diluted net loss per share was $6.81 compared with $4.69 a year ago. Non-GAAP net loss was $30,018,000 against $135,985,000 a year ago. Non-GAAP basic net loss per share was $1.61 against $12.05 a year ago. On a pro forma basis, net loss for the year ended December 31, 2017 was $30.0 million, compared to $136.0 million in 2016.